The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Statement of Commissioner Slaughter In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
Statement of Chairman Simons, Commissioner Phillips, and Commissioner Wilson In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
Statement of Commissioner Wilson In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
20190521: Kadant Inc.; Levine Leichtman Capital Partners Private Capital Solutions
20190186: Baylor Scott & White Holdings; Providence St. Joseph Health
20190538: Pentagon Federal Credit Union; Progressive Credit Union
20190540: ResMed Inc.; Reciprocal Labs Corporation
LG Electronics USA, Inc. (OLED televisions)
9140-9201 Québec Inc. (Premium Business Pages Inc.)
Watson Pharmaceuticals / Actavis Inc., In the Matter of
The FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive. The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
There is a related federal proceeding and two related administrative proceedings: